Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28637724 | 0.86 | CA12 (0.50) | CA12CA1CA2CA9TSHR | |
| SCHEMBL29233531 | 0.83 | — | — | |
| SCHEMBL10771408 | 0.74 | — | — | |
| SCHEMBL10196614 | 0.74 | — | — | |
| SCHEMBL10850846 | 0.74 | — | — | |
| SCHEMBL7236067 | 0.72 | — | — | |
| SCHEMBL2257027 | 0.72 | — | — | |
| SCHEMBL10158920 | 0.72 | — | — | |
| SCHEMBL9870252 | 0.72 | CA12 (0.50) | CA12CA1CA2CA9TSHR | |
| SCHEMBL134436 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0042688-B1 | WEED CONTROL USING 3-(4-ISOPROPYLPHENYL)-1,1-DIMETHYLUREA IN COMBINATION WITH S-2,3,3-TRICHLOROALLYL DIISOPROPYLTHIOCARBAMATE | MAY & BAKER LIMITED (GB) | 1984-01-18 | — | — | EP | claimed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-9765022-B2 | Disulfide compounds for delivery of pharmaceutical agents | TUFTS UNIVERSITY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170224839-A1 | NANOPARTICLES FOR DRUG DELIVERY | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160082126-A1 | NANOCOMPLEXES FOR DELIVERY OF SAPORIN | UNIV TUFTS (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160009643-A1 | DISULFIDE COMPOUNDS FOR DELIVERY OF PHARMACEUTICAL AGENTS | TRUSTEES OF TUFTS COLLEGE | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | CA12 3727/4885CA1 4251/4885CA2 4784/4885 |
| US-20160009643-A1 | DISULFIDE COMPOUNDS FOR DELIVERY OF PHARMACEUTICAL AGENTS | P4HB, PDIA6, PDIA5 | CA12 2187/4885CA1 2540/4885CA2 3160/4885 |
| US-20170224839-A1 | NANOPARTICLES FOR DRUG DELIVERY | MSN, CD47, MTHFD1 | CA12 123/4885CA1 254/4885CA2 597/4885 |
| US-20160082126-A1 | NANOCOMPLEXES FOR DELIVERY OF SAPORIN | SARNP, SAP30BP, SCP2 | CA12 2443/4885CA1 3034/4885CA2 3863/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | CA12 3727/4885CA1 4251/4885CA2 4784/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | CA12 3727/4885CA1 4251/4885CA2 4784/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | CA12 4043/4885CA1 4560/4885CA2 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.